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PURPOSE. Recent studies have reported neuroprotective effects
of erythropoietin (EPO) and vascular endothelial growth factor
(VEGF). The purpose of the present study was to clarify their
influence on neurite outgrowth and regeneration of rat retinal
ganglion cells (RGCs) in vitro and to elucidate the expression
of corresponding receptors in the rat retina in vivo.
METHODS. Retinal explants from postnatal rats were stimulated
with VEGF alone; VEGF in combination with anti-VEGF-recep-
tor (VEGF-R)-2 antibody or T-type Ca2 channel blocker etho-
suximide (ESX); EPO alone; or EPO in combination with anti-
EPO-receptor antibody or ESX. The presence of the
corresponding receptors in the rat retina was assessed by
reverse transcription-polymerase chain reaction (RT-PCR) and
by immunohistochemistry.
RESULTS. EPO induced a stable improvement of neurite out-
growth of RGCs in a dose-dependent manner (5  1015 M to
5  1013 M) up to 169% (P  0.05). Treatment of the
explants with anti-EPO-R antibody (1:80 dilution) and with ESX
(5 M) totally inhibited EPO-mediated effects on RGCs. In
comparison, VEGF (50 ng/mL), induced neurite outgrowth of
retina explants up to 167% (P  0.05), which again was
inhibited in the presence of anti-VEGF-R2 antibody or ESX.
Transcripts of EPO-R, VEGF-R1, and VEGF-R2 were detected by
RT-PCR. Intense immunoreactivity for VEGF-R1, VEGF-R2, and
EPO-R were found in the RGC layer of the retina.
CONCLUSIONS. The data demonstrate for the first time that EPO
and VEGF have a significant and specific biological effect on
neurite regrowth of axotomized RGCs. Therefore, these results
imply that EPO and VEGF have not only a neuroprotective but
also a neuroregenerative role in ischemic retinal conditions.
(Invest Ophthalmol Vis Sci. 2002;43:2021–2026)
Erythropoietin (EPO) is a hematopoietic cytokine with func-tions not only in erythrocyte development but also in the
nervous system.1,2 It is mainly produced by the kidney in
adults3 and by the liver in fetal stages.4 In the human fetus, EPO
expression is localized in the central nervous system (CNS),
cerebrospinal fluid, adrenal cortex, and neural retina.5–7
EPO exerts its biological functions in responsive cells in the
CNS through a 66-kDa cell surface receptor (EPO-R), which is
expressed in such areas of the brain as the cerebral cortex,
midbrain, and hippocampus.8,9 Astrocytes are able to synthe-
size EPO under insulin or insulin-like growth factor (IGF) stim-
ulation10 or under hypoxic conditions—for example, in isch-
emic insults.11 Therefore, EPO could be involved in providing
a better oxygen supply to the CNS. Furthermore, EPO has been
shown to protect primary cultured neurons from N-methyl-D-
aspartate (NMDA) receptor–mediated glutamate toxicity and
against ischemia-induced neuronal death.9,12 In vivo evidence
for a neuroprotective function of EPO has been demonstrated
in different models of hypoxic-ischemic injury11–14 and in an
animal model of Parkinson disease.15
Comparable results have been reported in studies of vascu-
lar endothelial growth factor (VEGF). VEGF, known as a potent
angiogenic factor, has similar neuroprotective properties.16,17
The angiogenic action of VEGF involves an antiapoptotic effect
on endothelial cells, which is mediated through the VEGF-
receptor (VEGF-R)-2. In oxygen-injured rat retina, upregulation
of the tyrosine kinase receptors VEGF-R1/flt-1 and VEGFR-2/
flk-1 were demonstrated.18
Neuronal survival mediated by neuroprotective factors and
neuronal regeneration in the CNS after injury are closely re-
lated. Despite the demonstrated benefits in neuroprotection,
there are no data available concerning EPO-induced stimula-
tion of neurite regeneration. Even though it has been reported
that VEGF, besides its neuroprotective effects, has a neurotro-
phic influence, by stimulating axonal outgrowth from dorsal
root ganglia or superior cervical ganglia in culture,19 data
describing the action of VEGF on axonal regeneration of cen-
tral intrinsic neurons are still unavailable.
Therefore, we wanted to clarify our hypothesis that EPO
has the potential to stimulate axonal regeneration of RGCs in
vitro by acting through the EPO-R. Furthermore, we wanted to
prove the existence of EPO-R’s expression in the retina. Addi-
tionally, we wanted to elucidate the effect of VEGF on axonal
outgrowth of central neurons.
MATERIAL AND METHODS
Animals
Fisher rats (F344) were used in all experiments according to the ARVO
Statement for the Use of Animals in Ophthalmic and Vision Research
and were kept under conditions of constant temperature and humidity
in a 12 hour light–dark cycle in the animal house of the University of
Kiel. Animals were mated overnight, and the day after mating was
counted as embryonic day (E)1. Pups were born after 22 days of
gestation, and the day of birth was counted as postnatal day (P)0.
Preparation of Retinal Explants and
Tissue Culture
Rat retinal explants (P11) were prepared and cultured in a three-
dimensional fibrin gel, as described.20 Briefly, the retinae were pre-
pared under semisterile conditions, and explants were punched out of
the retinae with a 400-m syringe needle. The retinal explants were
cultured at 37°C in humidified CO2-air (7.5%–92.5%) in a fibrin gel in
serum-free (control cultures) or drug-supplemented media for 3 days.
Cytokine and Drug Treatment
EPO (the kind gift of Janssen-Cilag, Neuss, Germany) was freshly
prepared by dissolving 84 g (10,000 U) in 1 mL distilled water.
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Ethosuximide (ESX; Sigma, Munich, Germany), a T-type Ca2 channel
blocker, was dissolved in ethanol to yield a 10-mM stock solution.
Polyclonal anti-EPO-R antibody (Upstate Biotechnology, Lake Placid,
NY) was diluted 1:80 and added to the cultures. VEGF (Biosource,
Solingen, Germany) was prepared from a 100-g/mL stock solution in
phosphate-buffered saline (PBS) containing 0.1% bovine serum albu-
min (BSA), and anti-VEGF-R2 antibody (R&D Systems, Minneapolis,
MN) was used in a concentration of 1 g/mL.
Evaluation of Neurite Outgrowth
After 3 days in vitro, the explant cultures were fixed in 2.5% glutaral-
dehyde by microwave irradiation (10 seconds, 50°C), dehydrated in
ethanol, stained with Sudan black (microwave irradiation, 1 minute,
50°C), and embedded in a mixture of glycerol and gelatin. Neurite
outgrowth was assessed using a computerized image-analysis system
(Analysis; SIS, Münster, Germany). The axonal domain of the retinal
explants was plotted by connecting the tips of the outgrowing neu-
rites. The area of this domain was then determined by measuring the
complete area and subtracting the area of the solid retinal explant. The




Total RNA from retinae (P10) was isolated and reverse transcribed (RT)
according to the manufacturer’s recommended protocol (Gibco BRL,
Eggenstein, Germany). RNA (5 g) was processed with reverse tran-
scriptase (Superscript; Gibco BRL) and Oligo(dT) primer (Amersham
Pharmacia Biotech, Freiburg, Germany). RT product (3 L) was then
amplified by polymerase chain reaction (PCR) using a specific EPO-R
primer pair (5-CTATGGCTGTTGCAACGCGA-3, sense), and (5-
CCGAGGGCACAGGA GCTT AG-3, antisense) as reported by Morishita
et al.9 To amplify the VEGF-R1 transcript, the primer pair 5-CAAGG-
GACTCTACACTTGTC-3 (sense) and 5-CCGAATAGCAGGCCTTC-
ACT-3 (antisense) was used, yielding a 240-bp PCR product, and the
primers 5-GCCAA-TGAAGGGGAACTGAAGAC-3 (sense) and 5-TCT-
GACTGCTGGTGATGCTGTCC-3 (antisense) were used for amplifica-
tion of the VEGF-R2 transcript, yielding a 537-bp product.21 cDNA
products were subjected to agarose gel electrophoresis (1.5%), and
fragments were visualized with ethidium bromide incorporation under
UV light. The rat -actin housekeeping gene was used as an internal
control to demonstrate that equivalent amounts of RNA had been
loaded.
Immunohistochemistry of EPO-R, VEGF-R1, and
VEGF-R2 in the Rat Retina
The animals were killed by transcardial perfusion with 4% paraformal-
dehyde in PBS. The eyes were removed and embedded in paraffin after
removal of the lens. Rehydrated sections (7 m) were incubated in
10% horse serum for 20 minutes to block nonspecific binding, washed
three times in PBS, and incubated for 1 hour with anti-EPO-R antibody
(rabbit polyclonal IgG, clone M-20, 1:100 dilution), anti-VEGF-R1 anti-
body (rabbit polyclonal IgG, clone c-17, 1:80 dilution), or anti VEGF-R2
antibody (mouse monoclonal IgG, clone A-3, 1:80 dilution). After a
wash in PBS, sections were incubated with goat anti-rabbit IgG (1:
1000, 1 hour; Vector Laboratories, Burlingame, CA). Immunohisto-
chemical staining was performed with the avidin-biotin complex tech-
nique according the manufacturer’s protocol (Vector). Negative
controls were performed by omitting the primary antibodies and in
parallel (for EPO-R) by preabsorbing the primary antibodies with a
10-fold (by mass) excess of a specific blocking peptide (Santa Cruz
Biotechnology, Inc., Heidelberg, Germany). Sections were photo-
graphed under a microscope (Axioplan; Carl Zeiss Inc., Thornwood,
NY) on TMX400 film (Eastman Kodak, Rochester, NY).
Statistical Analysis
All results are expressed as the mean  SEM. The significance of
differences was tested with ANOVA and Bonferroni (Fisher) test. P 
0.05 was considered statistically significant.
RESULTS
Control Cultures
After 3 days in vitro, many regenerating but short neurites were
visible, growing out from the whole circumference of the
retinal explants, reaching growth distances up to 180 m (Fig.
1A). Their responsiveness to brain-derived neurotrophic factor
(BDNF)22 confirmed that the regenerating neurites were pro-
cesses of RGCs (data not shown).
Effects of EPO and VEGF on Neurite Outgrowth
from RGCs
Compared with control explants (100%), EPO dose depen-
dently enhanced the axonal domain with a half-maximum con-
centration (EC50) of 7.8  10
15 M. In a concentration of 5 
1013 M (maximum concentration) EPO increased the neurite
elongation up to 169%  18% (n  18; Figs. 1D, 2). Most of the
RGCs extended their axons more than 400 m—some of them,
up to 650 m. The addition of VEGF (50 ng/mL) elongated the
neurites up to 167%  20% (n  18; Figs. 1E, 2). The length of
the majority of axons was in the range of more than 350 m.
Single axons reached distances of up to 600 m.
Effects of Anti-EPO-R Antibody, the T-Type Ca2
Channel Blocker ESX and Anti-VEGF-R2 Antibody
on Neurite Outgrowth
In the presence of anti-EPO-R antibody, the EPO-induced neu-
rite outgrowth was totally abolished (102%  8%, n  18; Figs.
1B, 2). Similar results were achieved in the presence of anti-
VEGF-R2 antibody after VEGF stimulation (Fig. 2). Coincuba-
tion with EPO (5  1013 M) or VEGF (50 ng/mL) and the
T-type Ca 2 channel blocker ESX (5 M) induced a reduction
of the EPO- and VEGF-mediated regenerative response to con-
trol levels (EPO: 101%  11%, n  18; VEGF: 108%  9%, n 
12; Figs. 1C, 2).
EPO-R, VEGF-R1, and VEGF-R2 Transcripts in the
Rat Retina
The presence of EPO-R, VEGF-R1, and VEGF-R2 in rat retinae
was analyzed by RT-PCR. Figure 3 shows an ethidium bromide–
stained agarose gel of PCR products from rat retina. In lane 2
the expected 240-bp PCR product of VEGF-R1 and in lane 3 the
537-bp product of VEGF-R2 cDNA are visible. The band in lane
4 represents the expected 402-bp PCR product of EPO-R
cDNA. Lane 5 shows -actin (279 bp), and the DNA migration
in a 100-bp DNA-ladder is seen in lane 1.
Immunohistochemistry
To localize EPO-R, VEGF-R1, and VEGF-R2 in the adult rat
retina, immunohistochemical studies were performed. Positive
EPO-R immunostaining was detectable in different layers of the
rat retina, with the most intensive immunostaining identifiable
in the RGC layer. Less intensive labeling was depicted in the
inner and outer plexiform layers and in the inner portion of the
inner segments (Fig. 4A). The EPO-R–specific staining was
confirmed by coincubation of the anti-EPO-R antibody with the
EPO-R–specific blocking peptide (Fig. 4B).
Positive immunolabeling of VEGF-R1 (Fig. 4C) and of VEGF-
R2–bearing cells (Fig. 4D) showed comparable results in the
RGC layer.
DISCUSSION
The hematopoietic cytokine EPO and the angiogenic factor
VEGF have been demonstrated to exert neuroprotective effects
(e.g., during hypoxia in vitro and in vivo12,16) in -amino-3-
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hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)–mediated
cytotoxicity23 and in an animal model of parkinsonism.15
In this article, we present evidence that EPO is also capable
of stimulating neurite outgrowth in neurons of the rat retina in
vitro—a hitherto unknown function of EPO in the CNS. We
also complement and extend the findings on the neurotrophic
potency of the angiogenic factor VEGF,16,19 by demonstrating
a robust axonal outgrowth of rat retinal ganglion cells (RGCs)
stimulated with VEGF in vitro. Both peptides are induced
under hypoxic conditions by the basic helix-loop-helix tran-
scription factor HIF-1 (hypoxia-induced factor-1; see Ref. 24 for
review).
In our three-dimensional tissue culture system of retinal
explants, the ability of RGCs to extend their axons is compa-
rable to that of other adult mammalian CNS neurons.25,26 The
limited regenerative capacity is reflected in the control exper-
iments where the explants were cultured in serum-free me-
dium, and only abortive axonal sprouts were visible. However,
the addition of growth-promoting molecules, such as BDNF (10
ng/mL) or ANG II (5  106 M),22 induces an enhanced
outgrowth of axons from the whole circumference of the
explants. Hence, if supplied with the appropriate neurotrophic
substrates, postnatal RGCs are able to regenerate their axons in
this system, which may serve as a reliable model for the
investigation of potential neuroprotective–neuritogenic mole-
cules for CNS neurons. An effect similar to 10 ng/mL of BDNF
is elicited by the administration of either EPO (5  1013 M) or
VEGF (50 ng/mL).
VEGF and Neurite Outgrowth of RGCs
Sondell et al.19 recently reported that VEGF stimulates axonal
outgrowth from mouse superior cervical ganglion and dorsal
root ganglion cells through the flk-1 receptor (VEGF-R2). Their
results of VEGF-mediated effect on axonal outgrowth can now
be extended to a subset of CNS neurons: postnatal RGCs. We
cannot deliver direct evidence that the neuritogenic effect of
VEGF in RGCs is mediated through the flk-1 receptor, because
the receptor antagonist SU5416 (Sugen, South San Francisco,
CA) has not been made available yet, but we demonstrate that
VEGF-induced neurite outgrowth could be blocked by an anti-
VEGF-R2 antibody or by addition of ESX, a T-type calcium
channel blocker. Furthermore, transcript and protein of the
VEGF receptor flk-1 (VEGF-R2) are strongly expressed in the
RGC layer of adult rats. Jin et al.17 demonstrated that the
VEGF-induced neuroprotection is mediated through a VEGF-
R2–dependent activation of the phosphatidylinositol 3 kinase
(PI3-K)/Akt signaling pathway, which also promotes cell sur-
vival and proliferation of vascular endothelial cells.27 Because
PI3-K/Akt has been shown to enhance axonal regeneration in
motoneurons and directly mediates the neuroprotective effects
of IGF-1 in RGCs,28 it is likely to hypothesize that activation of
FIGURE 1. Retinal (P10) explants af-
ter 3 days in vitro. (A) Many regener-
ating but short neurites were de-
tected in control culture. (D) In the
presence of EPO, the number and
length of neurites were increased up
to 169%  19%. Coincubation of EPO
with anti-EPO-R antibody (B) or the
T-type Ca channel blocker ESX (C)
totally abolished the EPO-induced ax-
onal outgrowth. (E) Addition of
VEGF to retinal explants enhanced
the neurite growth up to 167% 
17%. Bar, 100 m.
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the PI3-K/Akt signaling pathway may be a key event in the
demonstrated VEGF-evoked neurite outgrowth of rat RGCs.
Response of RGC Axons to EPO
Our results suggest that the EPO-induced growth response is
mediated directly through EPO-Rs on RGCs. Transcribed
mRNA of the EPO-R gene is present in the adult retina, and a
predominant expression of EPO-R in the RGC layer was visu-
alized by immunohistochemistry. Coincubation with EPO-R–
blocking antibodies totally abolished the effects on neurite
outgrowth of the retinal explants.
Besides its well-known action on the hematocrit, EPO has
been implicated in the process of angiogenesis (e.g., Ref. 2),
pointing toward a possible role of an improved blood supply
for the neuroprotective actions of EPO during ischemic insults
and diabetic macular retinopathy.29 Furthermore, EPO has
been reported to act as an anti-apoptotic agent30 or as an
antioxidant,31 both of which could explain the neuroprotec-
tive effects described so far. Although vascularization or eryth-
ropoietic effects of EPO can be excluded in the assay system
we used, we cannot completely rule out the possible action of
EPO on glial cells stimulating the release of other neurotrophic
factors that may act on RGCs in a paracrine manner. In con-
trast, immunohistochemical staining did not reveal a distinct
expression of EPO-R on Müller cells in the adult retina, making
EPO-responsiveness of only the glial elements in the retina
rather unlikely.
Intracellular Signaling through EPO-R
The intracellular signaling pathways of EPO-R in neuronal cells
is not yet fully understood. From the studies of other cell
populations and a study by Assandri et al.32 in human neuro-
blastoma cells, it is tempting to speculate that the EPO-medi-
ated regulation of calcium fluxes might be involved in eliciting
the axonal growth response. Calcium has been shown to be
pivotal in the processes of neurite extension and growth cone
guidance (for review, see Ref. 33). As reported in a paper by
Archer et al.,34 the positive effects of the FGF receptor and L1
on axonal outgrowth is blocked when calcium channel block-
ers are administered. In our hands, the T-type calcium-channel
blocker ESX blocked the neuritogenic effect both of EPO and
VEGF. In rat pheochromocytoma cells (PC12) a calcium-depen-
dent increase in mitogen-activated protein kinase (MAPK) ac-
tivity has been demonstrated on EPO-stimulation.35 These
mechanisms may also be involved in the calcium-dependent
growth response elicited by EPO-R or VEGF-R in the retinal
explants.
In recent studies, it has been shown that another crucial
element of EPO-R signaling consists of the activation of tran-
scription factors of the signal transducer and activator of tran-
scription (STAT) family.36 The EPO-R associates with JAK2, a
member of the Janus-protein kinases, thereby converting latent
cytoplasmic STAT-transcription factors into their active form
through tyrosine phosphorylation. The ability to inhibit apo-
ptotic signals in erythroid progenitor cells through STAT5-
dependent induction of bcl-xL gene expression,37,38 taken to-
gether with our results that caspase-1 inhibition mediates
neurite outgrowth from retinal explants,39 shows a potential
contribution of the JAK/STAT pathway in EPO-mediated neu-
roprotection–growth stimulation of CNS axons. Ciliary neuro-
trophic factor (CNTF), a known neurotrophic factor for RGCs,
activates STAT3 in RGCs and Müller cells, when directly ad-
ministered into the vitreous body, supporting a neuroprotec-
tive–regenerative role of STAT factors.40 The direct involve-
ment of the JAK/STAT pathway in EPO signaling in axotomized
RGCs is currently under investigation.
Should our in vitro findings be verified by comparable in
FIGURE 2. Effect of EPO and VEGF
on neurite outgrowth of retinal ex-
plants (P10). EPO increased the ax-
onal regeneration in comparison
with control culture. The effect of
EPO on axonal elongation was
blocked by anti-EPO-R antibody (Ab)
or by the T-type calcium blocker ESX
(5 M). VEGF (50 ng/mL) exerted a
similar effect on axonal regeneration,
and this effect was blocked by anti-
VEGF-R2 antibody or by the T-type
calcium blocker ESX (5 M). In all
experimental groups, n  18, except
VEGFESX, n  12. Data are ex-
pressed as the mean  SEM; *P 
0.05 compared with the control.
FIGURE 3. Detection of EPO-R, VEGF-R1, and VEGF-R2 mRNA in the
P10 rat retina. RT-PCR products were visualized with agarose gel
electrophoresis in the presence of ethidium bromide. Electrophoresis
of RT-PCR products yielded bands of expected sizes: Lane 1: DNA
migration on a 100-bp ladder; lane 2: 240 bpm, VEGF-R1; lane 3: 537
bp, VEGF-R2; lane 4: 402 bp, EPO-R; lane 5: 279 bp, -actin.
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vivo studies, the results would further elucidate the novel view
of extensive crosstalk between the hematopoietic cells and the
CNS, where neural stem cells can repopulate depleted bone
marrow,41 and hematopoietic cytokines are able to stimulate
axonal regeneration (this study) or the differentiation patterns
of expanded CNS precursors.42
Possible Therapeutic Relevance
Retinal diseases such as glaucoma, central artery occlusion, and
diabetic retinopathy, are characterized by progressive damage
to RGC axons and RGC death. They are among the leading
causes of blindness, and, at present, neuroprotective therapies
for these debilitating diseases remain unavailable. Based on the
findings described herein, we propose that the EPO/EPO-R
system (and possibly the VEGF/VEGF-R system) could provide
an endogenous mechanism that may protect the retina against
damages of different origin and may also promote axonal re-
generation in CNS lesions. However, reports of a potentially
harmful role of VEGF, through VEGF-R2, in the pathogenesis of
neovascularizing retinal diseases must be carefully consid-
ered.43,44 Because a proangiogenic role has been described,
not only for VEGF, but also for EPO, further elucidation of the
respective signaling pathways seems an absolute prerequisite
to molecular dissection of the stimulation of axonal outgrowth
from potentially harmful angiogenic effects.
Considering recent findings that could demonstrate neuro-
trophic actions of a truncated EPO peptide through EPO-R
without the untoward effects of stimulating erythropoiesis and
raising the hematocrit,45 a selectively designed “neuro-EPO”
might provide a basis for novel, receptor-directed therapeutic
strategies for a plethora of retinal ischemic diseases.
FIGURE 4. Immunohistochemical
detection of EPO-R (A), VEGF-R1 (C),
and VEGF-R2 (D) in the rat retina. (A)
Note the intensive immunoreactivity
of the ganglion cell layer (GCL) as
well as the moderate staining of the
inner (IPL) and outer plexiform lay-
ers (OPL) and the inner portion of
the inner segment (IIS). (B) Nega-
tive control: EPO-R immunoreactivity
preabsorbed with blocking peptide.
Strong immunolabeling of VEGF-R1
(C) and VEGF-R2 (D) in the GCL.
Original magnification, 400.
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